SCHEMBL16438394

SCHEMBL16438394

CCCCCCNc1ncc(C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc2)c(N[C@H]2CC[C@H](O)CC2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MERTK Q12866 20/20 1.00
▸ AXL P30530 10/20 1.00
▸ TYRO3 Q06418 9/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16435405 1.00 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16429264 0.98 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16429263 0.98 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16435385 0.98 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16435394 0.95 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16438395 0.95 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16435433 0.95 MERTK (1.00) MERTKAXLTYRO3
SCHEMBL16435409 0.93 MERTK (0.96) MERTKAXLTYRO3
SCHEMBL16438279 0.93 MERTK (0.96) MERTKAXLTYRO3
SCHEMBL16435397 0.93 MERTK (1.00) MERTKAXLTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9649309-B2 Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-05-16 — — US disclosed
US-9567326-B2 Pyrimidine compounds for the treatment of cancer THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2017-02-14 — — US disclosed
WO-2015157127-A1 THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-15 — — WO disclosed
US-20150290194-A1 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 — — US disclosed
US-20150038481-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290194-A1 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY MERTK, FLT3, TK1 MERTK 1/4885AXL 16/4885TYRO3 41/4885
US-20150038481-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER DPYD, TYMP, TYMS MERTK 2234/4885AXL 942/4885TYRO3 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback